MRKR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Marker Therapeutics Inc (MRKR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive trading signals, and the company's financial performance shows significant declines in revenue, net income, and EPS. Additionally, technical indicators do not suggest an immediate entry point. While the analyst rating is positive with a high price target, the lack of recent news, neutral insider and hedge fund activity, and absence of congress trading data make this stock more of a speculative hold than a confident buy.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 37.86, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 1.495, with support at 1.354 and resistance at 1.637.
H.C. Wainwright initiated coverage with a Buy rating and a $10 price target, citing the company's innovative MAR-T cell therapies and potential leadership in cancer immunotherapy.
The company's financials for Q3 2025 show a significant decline in revenue (-35.99% YoY), net income (-13.41% YoY), and EPS (-53.85% YoY). Technical indicators suggest bearish momentum, and there is no recent news or trading activity from insiders, hedge funds, or congress.
In Q3 2025, revenue dropped by 35.99% YoY to $1,232,938. Net income decreased by 13.41% YoY to -$1,998,662, and EPS fell by 53.85% YoY to -$0.12. Gross margin remained stable at 100%.
H.C. Wainwright initiated coverage with a Buy rating and a $10 price target, highlighting the company's innovative pipeline and potential leadership in cancer immunotherapy.
